Epidermal growth factor receptor (EGFR) driver mutation cancers represent a distinct subset of non-small-cell lung cancer (NSCLC) with broad molecular and clinical heterogeneity (1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.